-
3,5-dimethyl 4-{3-[({3-[4-(3-methoxyphenyl)piperidin-1-yl]propyl}carbamoyl)amino]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
-
ChemBase ID:
154770
-
Molecular Formular:
C33H42N4O6
-
Molecular Mass:
590.70978
-
Monoisotopic Mass:
590.31043508
-
SMILES and InChIs
SMILES:
CC1=C(C(C(=C(N1)C)C(=O)OC)c1cccc(c1)NC(=O)NCCCN1CCC(CC1)c1cccc(c1)OC)C(=O)OC
Canonical SMILES:
COc1cccc(c1)C1CCN(CC1)CCCNC(=O)Nc1cccc(c1)C1C(=C(C)NC(=C1C(=O)OC)C)C(=O)OC
InChI:
InChI=1S/C33H42N4O6/c1-21-28(31(38)42-4)30(29(22(2)35-21)32(39)43-5)25-10-6-11-26(19-25)36-33(40)34-15-8-16-37-17-13-23(14-18-37)24-9-7-12-27(20-24)41-3/h6-7,9-12,19-20,23,30,35H,8,13-18H2,1-5H3,(H2,34,36,40)
InChIKey:
WMYSXJSJXZFODY-UHFFFAOYSA-N
-
Cite this record
CBID:154770 http://www.chembase.cn/molecule-154770.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
3,5-dimethyl 4-{3-[({3-[4-(3-methoxyphenyl)piperidin-1-yl]propyl}carbamoyl)amino]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
|
|
|
IUPAC Traditional name
|
3,5-dimethyl 4-{3-[({3-[4-(3-methoxyphenyl)piperidin-1-yl]propyl}carbamoyl)amino]phenyl}-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
|
|
|
Synonyms
|
1,4-dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-dimethyl ester-3,5-pyridinedicarboxylic acid
|
BMS-193885
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
13.507421
|
H Acceptors
|
6
|
H Donor
|
3
|
LogD (pH = 5.5)
|
-0.2738498
|
LogD (pH = 7.4)
|
1.6084893
|
Log P
|
3.1954732
|
Molar Refractivity
|
169.4097 cm3
|
Polarizability
|
63.783947 Å3
|
Polar Surface Area
|
118.23 Å2
|
Rotatable Bonds
|
12
|
Lipinski's Rule of Five
|
false
|
DETAILS
DETAILS
Sigma Aldrich
Sigma Aldrich -
B5063
|
Biochem/physiol Actions BMS-193885 is a potent, selective Y1 antagonist that is active in both acute and chronic animal models of food intake. Although it is active in vivo, it is not orally bioavailable due to poor intestinal absorption, so it is not being pursued for pharmaceutical development. BMS-193885 has been used as a pre-clinical proof of concept tool for showing efficacy of Y1 antagonism in treating obesity. |
PATENTS
PATENTS
PubChem Patent
Google Patent